Chemerin levels in patients with coronary artery disease

ObjectivesTo evaluate chemerin levels in patients with coronary artery disease and detect the correlation between these levels (if any) with the severity of coronary artery disease.BackgroundRecent evidence demonstrated that the circulating adipokines were associated with the onset of coronary artery disease (CAD). As a novel adipokine; chemerin has been related to atherosclerosis and the presence of coronary artery disease. However, the plasma levels of chemerin in patients with acute coronary syndrome (ACS) have yet to be investigated.MethodsThis study a prospective case-control study included 96 participates undergoing coronary angiography at cath lab, cardiology department-Menoufia University from January 2018 to September 2018. Serumchemerin levels weremeasured by an enzyme-linked immunosorbent assay (ELISA). Echocardiography, electrocardiography and routine laboratory investigations were done. The severity of coronary stenosis was estimated usingGensini, vessel and severity coronary scores.ResultsAmong the 96 patients, 4groups were described: group I included 24 Acute myocardial infarction (AMI) patients, 30 unstable angina (UA) patients in group II, 27 stable angina (SA) patients inGroup III, 15 patients with normal coronary artery findings (control group) in Group IV. Serumchemerin levels were significantly higher in AMI and UA groups than SAand control groups P < 0.001. Also there was a high significant positive correlation between serum chemerin levels and severity of CAD as regard to Gensiniscore P < 0.001, severity score P < 0.001 and vessel score P = 0.005.ConclusionChemerin is a novel biomarker for CAD and it was significantly correlated with various metabolic risk factors and atherosclerotic cardiovascular disease.